Research groups from the Department of Organic Chemistry and Inorganic Chemistry and the Department of Systems Biology of the University of Alcalá have developed pyridazino[2,3-a]pirrolo[2,1-c]-quinoxalinium salts as therapeutic agents in the treatment of leishmaniasis, metabolic syndrome, diabetes and obesity. The compounds exhibit high activity and selectivity for the Leishmania parasite, and they provide a new therapeutic tool for the treatment of type 2 diabetes.
The group seeks pharmaceutical companies to reach licensing agreements or collaboration and commercial agreements with technical assistance.
New and innovative aspects
As leishmanicidal, these compounds are highly selective. They can be used with other pharmaceuticals or additional active principles to provide a combination therapy.
As inhibitors of PTP1B, these compounds provide a new pharmacophore structure.
Main advantages of its use
High specificity for the Leishmania parasite.
Possible new therapy for diabetes and obesity.
Specifications
- The invention relates to the preparation of new compounds of Formula I as well as to the uses of these compounds to inhibit the growth and infection of the Leishmania parasite, which is an important new tool from the medical and veterinary point of views.
- The invention also relates to the use of these compounds to inhibit PTP1B (protein belonging to the family of protein tyrosine phosphatases, PTPs).
The composition comprises at least one of the compounds of the invention together with a pharmaceutically acceptable carrier. The use of this composition for the treatment of infectious diseases is as a therapeutically effective amount. It can be prepared as a solid or aqueous suspension, in an acceptable pharmaceutically solvent and may be administered by a suitable administration route. The compounds of the invention are prepared from pirroloquinoxalines.
It can be used for the treatment of insulin resistance, glucose intolerance, obesity, diabetes mellitus, hypertension and ischemic diseases. Moreover, these compounds can be used in the treatment of cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involved with inflammation and the immune system.
The present invention also concerns the use of these compounds for the treatment of renal failure, myocardial infarction, ischemia, multiple sclerosis, neurodegenerative diseases or infectious diseases such as leishmaniasis.
Applications
Intellectual property status
Patent granted
Current development status
Development phase
Desired business relationship
The group seeks pharmaceutical companies to reach licensing agreements or collaboration and commercial agreements with technical assistance.
The Technology Transfer Office at Alcalá University serves as a liaison between the University and its socioeconomic environment in terms of research and innovation. It encorages collaboration between research groups from universities and companies/institutions, with the objective to promote and commercialize research results and scientific capabilities.
Some of the services offered by this office are specified in the following list:
- Promotion of R & D and improvement of the relationships with companies.
- Promote the participation in R & D projects applicants to public calls (regional, national and European).
- Advising, processing and monitoring of patents and other forms of industrial protection.
- Support in the negotiation of contracts and agreements for R&D&i
Create your free account to connect with Universidad de Alcalá-OTRI and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Universidad de Alcalá-OTRI
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
![Salts of pyridazino[2,3-a]pyrrolo[2,1-c]quinoxaline for the treatment of leishmania infections and diseases that involve the protein tyrosine phosphatise 1B (metabolic syndrome, diabetes and obesity)](https://static0.innoget.com/uploads/thumb/wide//uploads//3df023970d7a042a76c022ad05180fd34bba60d6.jpg)
